Johnson & Johnson ENSEMBLE Trial for Its COVID-19 Vaccine Candidate
Johnson & Johnson (JNJ) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial, ENSEMBLE, for its COVID-19 vaccine candidate, JNJ-78436735. The initiation of the ENSEMBLE trial follows positive interim results from Phase 1 . . .
This content is for paid subscribers.
Impacting News September 29, 2020